Edora 8 DR-T, Evity 8 DR-T, Enitra 8 DR-T, Enticos 8 DR-T, Evity 6 DR-T, Enitra 6 DR-T, Edora 8 DR, Enitra 6 DR, Edora 8
Biotronik, Inc. · Decision date Oct 22, 2026
What did the FDA decide?
The FDA record for P950037/S299 describes a 30-day notice filed by Biotronik, Inc. under the reason Process Change - Manufacturer/Sterilizer/Packager/Supplier. The stated change is "updating visual and dimensional incoming inspection testing for certain components and raw materials used in IPG, ICD, and lead manufacturing." In plain terms, incoming inspection for selected components and raw materials used in implantable pulse generator, implantable cardioverter defibrillator, and lead production is being revised on visual and dimensional criteria. The notice does not specify which components or raw materials, what the prior testing was, what replaces it, or the acceptance criteria.
The identifier ties this to PMA P950037, a supplement numbered S299, so the action amends the existing approval rather than constituting a new approval of the whole system. The device category is implantable pacemaker pulse-generator, product code DXY, cardiovascular specialty, with decision OK30 dated 2026-10-22. The stated purpose concerns inspection testing only; the record offers no independent evidence on safety, clinical effectiveness, or any change in indications, and it should not be read as such.
FDA approval order statement
updating visual and dimensional incoming inspection testing for certain components and raw materials used in IPG, ICD, and lead manufacturing
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Oct 22, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P950037/S299
- Regulatory pathway
- PMA supplement
- Applicant
- Biotronik, Inc.
- Product code
- DXY
- Decision code
- OK30
- Decision date
- Oct 22, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: implantable pacemaker Pulse-generator.
- Applicant
- Biotronik, Inc.
- Product code
- DXY
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P950037. Subsequent supplements may change the device or its indications.
FDA decision timeline
P950037 · Original PMA
DROMOS DR/DR-A AND DROMOS SR/SR-B CARDIAC PACING SYSTEMS
P950037/S291 · Related supplement
PSW 2601.U, NEO 2601.U, Amvia Sky HF-T QP, Amvia Sky HF-T, Amvia Edge HF-T QP, Amvia Sky DR-T, Amvia Sky SR-T, Amvia Edg
P950037/S299 received
Application receipt date recorded by FDA.
P950037/S279 · Related supplement
Edora 8 DR-T 407145, Evity 8 DR-T 407146, Enitra 8 DR-T 407147, Enticos 8 DR-T 407148, Evity 6 DR-T 407149, Enitra 6 DR-
P950037/S296 · Related supplement
Edora 8 DR-T 407145; Evity 8 DR-T 407146; Enitra 8 DR-T 407147; Enticos 8 DR-T 407148; Evity 6 DR-T 407149; Enitra 6 DR-
P950037/S298 · Related supplement
Edora 8 DR-T, Evity 8 DR-T, Enitra 8 DR-T, Evity 6 DR-T, Enitra 6 DR-T, Edora 8 DR, Enitra 6 DR, Enticos 4 DR, Enticos
P950037/S289 · Related supplement
BIOexpress
P950037/S299 · FDA decision
30-Day Notice
P950037/S300 · Related supplement
Amvia Sky DR-T, Amvia Sky SR-T; Amvia Edge DR-T, Amvia Edge SR-T; Solvia Rise DR-T, Solvia Rise SR-T; Amvia Sky HF-T QP,
Timeline entries are records held by MedtechLedger for P950037. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P950037
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Biotronik, Inc. | PMA approval | Oct 11, 1996 | FDA | |
| Biotronik, Inc. | PMA supplement | Sep 17, 2026 | FDA | |
| Biotronik, Inc. | PMA supplement | Sep 25, 2026 | FDA | |
| Biotronik, Inc. | PMA supplement | Oct 9, 2026 | FDA | |
| Biotronik, Inc. | PMA supplement | Oct 13, 2026 | FDA | |
BIOexpressP950037/S289 | Biotronik, Inc. | PMA supplement | Oct 16, 2026 | FDA |
| Biotronik, Inc. | PMA supplement | Oct 28, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Biotronik, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 6024 Jean Rd., Lake Oswego, OR, 97035
Sources and methodology
- Original FDA record: P950037/S299
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records




